SCHEMBL5788367

SCHEMBL5788367

Cc1cc(N2CCCC2)nc(C=Cc2ccncc2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.57
GBA1 P04062 3/20 0.48
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 2/20 0.42
USP2 O75604 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTT P42858 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5788363 1.00 PDE10A (0.57) PDE10AGBA1CRHBPCRHR2SMN1; SMN2
SCHEMBL5789954 0.83 NUDT1 (0.51) PDE10ASMN1; SMN2ALDH1A1KDM4ENPSR1
SCHEMBL5789949 0.83 NUDT1 (0.51) PDE10ASMN1; SMN2ALDH1A1KDM4ENPSR1
SCHEMBL5789461 0.83 PDE10A (0.54) PDE10AGBA1CRHBPCRHR2SMN1; SMN2
SCHEMBL5791016 0.83 PDE10A (0.54) PDE10ACRHBPCRHR2SMN1; SMN2L3MBTL1
SCHEMBL5791625 0.83 PDE10A (0.54) PDE10ACRHBPCRHR2SMN1; SMN2L3MBTL1
SCHEMBL5789458 0.83 PDE10A (0.54) PDE10AGBA1CRHBPCRHR2SMN1; SMN2
SCHEMBL5791619 0.83 PDE10A (0.54) PDE10ACRHBPCRHR2SMN1; SMN2L3MBTL1
SCHEMBL5791021 0.83 PDE10A (0.54) PDE10ACRHBPCRHR2SMN1; SMN2L3MBTL1
SCHEMBL5790184 0.82 ALDH1A1 (0.54) PDE10ACRHBPCRHR2SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6657060-B2 Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia HOFFMAN-LA ROCHE INC. 2003-12-02 US claimed
US-20020086858-A1 Pyrimidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2002-07-04 US claimed
EP-1335906-B1 PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2006-09-27 EP disclosed
US-6657060-B2 Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia HOFFMAN-LA ROCHE INC. 2003-12-02 US disclosed
US-20020086858-A1 Pyrimidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086858-A1 Pyrimidine derivatives NPY1R, NPY5R, NPY4R PDE10A 2005/4885GBA1 4044/4885CRHBP 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.